SE4:E8: From Discovery to Process, Part 2: Getting Ugi with it - scaling a 3CL protease inhibitor
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
SE4:E8: From Discovery to Process, Part 2: Getting Ugi with it - scaling a 3CL protease inhibitor
-
ナレーター：
-
著者：
概要
In Part 2 of our Pharm to Table deep dive on MK‑7845, Dani and LC shift from invention to implementation, welcoming process chemists Nastaran Salehi Marzijarani and Ben Turnbull to the pod. We explore how the team re‑imagined the synthesis to enable robust, scalable supply—and why a classic multicomponent reaction you probably remember from school, the Joullié–Ugi reaction, ended up stealing the show. Along the way, we unpack route selection trade‑offs, lifecycle thinking in process chemistry, and what it really takes to bring an antiviral to life at scale.
Read and listen to some of the papers we discussed today:
Asymmetric Synthesis of MK-7845, an Investigational Treatment for COVID-19 - Org. Lett.
Part 1 of MK-7845 series: SE4:E7: From Discovery to Process, Part 1: Building a 3CL Protease Inhibitor Through Smart Fluorine Placement and Design Intuition
Follow the Pharm to Table podcast on X - @PharmtoTablePod
Visit our website at https://podcasters.spotify.com/pod/show/pharm-to-table